

## Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims

Claim 1. (cancelled)

Claim 2. (previously presented) A pharmaceutical composition comprising a core containing rivastigmine as a pharmacologically active agent, and a coating which comprises an inner film and an outer film.

Claim 3. (currently amended) A pharmaceutical composition according to claim [[1]] 2 wherein the outer film is permeable to water or body fluids.

Claim 4. (currently amended) A pharmaceutical composition according to claim [[1]] 2 wherein the coating has a thickness of 50 to 800 micrometers.

Claim 5. (currently amended) A pharmaceutical composition according to claim [[1]] 2 wherein said core releases an effective dose of the active agent 6 to 12 hours after ingestion.

Claims 6 and 7. (cancelled)

Claim 8. (new) A two-pulse release pharmaceutical composition comprising: 1) a first component comprising a therapeutically effective amount of rivastigmine wherein 70 to 95% of said rivastigmine is released in water within 3 to 4 hours; and 2) a second component comprising a core containing a therapeutically effective amount of rivastigmine and a coating wherein the coating comprises an outer film and an inner film, the inner film being in the form of a membrane which is semi-permeable to water or body fluids, and wherein rivastigmine is released 6 to 12 hours after ingestion.